116 related articles for article (PubMed ID: 30382885)
1. Structure-based assessment and network analysis of targeting 14-3-3 proteins in prostate cancer.
Root A; Beizaei A; Ebhardt HA
Mol Cancer; 2018 Oct; 17(1):156. PubMed ID: 30382885
[TBL] [Abstract][Full Text] [Related]
2. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.
Menon R; Deng M; Rüenauver K; Queisser A; Peifer M; Pfeifer M; Offermann A; Boehm D; Vogel W; Scheble V; Fend F; Kristiansen G; Wernert N; Oberbeckmann N; Biskup S; Rubin MA; Adler D; Perner S
J Pathol; 2013 Dec; 231(4):505-16. PubMed ID: 24114522
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
Biron E; Bédard F
J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
[TBL] [Abstract][Full Text] [Related]
4. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of YWHAZ expression in localized prostate cancer.
Rüenauver K; Menon R; Svensson MA; Carlsson J; Vogel W; Andrén O; Nowak M; Perner S
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):310-4. PubMed ID: 25156059
[TBL] [Abstract][Full Text] [Related]
6. Targeting the signalling pathways regulated by deubiquitinases for prostate cancer therapeutics.
Islam MT; Zhou X; Chen F; Khan MA; Fu J; Chen H
Cell Biochem Funct; 2019 Jul; 37(5):304-319. PubMed ID: 31062387
[TBL] [Abstract][Full Text] [Related]
7. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
8. Small molecules modulation of 14-3-3 protein-protein interactions.
Mori M; Vignaroli G; Botta M
Drug Discov Today Technol; 2013 Dec; 10(4):e541-7. PubMed ID: 24451646
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule binding sites to explore protein-protein interactions in the cancer proteome.
Xu D; Jalal SI; Sledge GW; Meroueh SO
Mol Biosyst; 2016 Oct; 12(10):3067-87. PubMed ID: 27452673
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
Butler MS; Roshan-Moniri M; Hsing M; Lau D; Kim A; Yen P; Mroczek M; Nouri M; Lien S; Axerio-Cilies P; Dalal K; Yau C; Ghaidi F; Guo Y; Yamazaki T; Lawn S; Gleave ME; Gregory-Evans CY; McIntosh LP; Cox ME; Rennie PS; Cherkasov A
Oncotarget; 2017 Jun; 8(26):42438-42454. PubMed ID: 28465491
[TBL] [Abstract][Full Text] [Related]
11. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
12. Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer.
Ebhardt HA; Root A; Liu Y; Gauthier NP; Sander C; Aebersold R
NPJ Syst Biol Appl; 2018; 4():26. PubMed ID: 29977602
[TBL] [Abstract][Full Text] [Related]
13. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
15. Differential proteome expression analysis of androgen-dependent and -independent pathways in LNCaP prostate cancer cells.
Cha S; Shin DH; Seok JR; Myung JK
Exp Cell Res; 2017 Oct; 359(1):215-225. PubMed ID: 28736082
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
[TBL] [Abstract][Full Text] [Related]
18. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.
Qiu JX; Zhou ZW; He ZX; Zhao RJ; Zhang X; Yang L; Zhou SF; Mao ZF
Drug Des Devel Ther; 2015; 9():349-417. PubMed ID: 25609920
[TBL] [Abstract][Full Text] [Related]
19. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
Liu Z; Zhu G; Getzenberg RH; Veltri RW
J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
[TBL] [Abstract][Full Text] [Related]
20. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
